ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Explore Matthews International Corporation's restructuring efforts, asset sales, and challenges in reducing debt. Click for ...

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.” ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

India needs to build a much stronger drug discovery ecosystem to compete globally, says former GSK Pharma MD Annaswamy ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

LEAP addresses those needs head-on with a local-first approach that allows small models to run directly on-device, no cloud ...

The UK's FTSE 100 index fell after reaching record highs, impacted by rising U.S. inflation and potential Bank of England ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...